Conventional therapies deplete brain-Infiltrating adaptive immune cells in a mouse model of group 3 medulloblastoma implicating myeloid cells as favorable immunotherapy targets, Zahra Abbas, Courtney George, Mathew Ancliffe, Meegan Howlett, Anya C. Jones, Mani Kuchibhotla, Robert J. Wechsler-Reya, Nicholas G. Gottardo, Raelene Endersby
Research outputs 2022 to 2026

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma, Victoria Atkinson, Adnan Khattak, Andrew Haydon, Melissa Eastgate, Amitesh Roy, Prashanth Prithviraj, Christian Mueller, Chrystelle Brignone, Frederic Triebel
Research outputs 2014 to 2021

The prognostic impact of circulating tumour dna in melanoma patients treated with systemic therapies—beyond braf mutant detection, Gabriela Marsavela, Peter A. Johansson, Michelle R. Pereira, Ashleigh C. McEvoy, Anna L. Reid, Cleo Robinson, Lydia Warburton, Muhammad A. Khattak, Tarek M. Meniawy, Benhur Amanuel, Michael Millward, Nicholas K. Hayward, Melanie R. Ziman, Elin S. Gray, Leslie Calapre
Research outputs 2014 to 2021